Drugs / L-Lysine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | LysaKare | — | 2019-07-25 | europa.eu ↗ |
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05210504 | Mar 2022 → Jan 2023 | type 2 diabetes mellitus | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02756117 | May → Oct 2016 | prediabetes syndrome | Vanderbilt University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00996242 | Sep 2007 → Sep 2008 | schizophrenia | Göteborg University | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06580145 Comparator | Feb 2025 → Jun 2028 expected | major depressive disorder | Emory University | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01579799 Comparator | Apr → Aug 2012 | — | University of Zurich | Completed | No outcome recorded |
| — | NCT01208324 Comparator | Mar 2010 → Nov 2018 | premature menopause | University of Colorado, Denver | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-lysine | “L-Lysine (4.8 g)” NCT01208324 ↗ |
| Modality | Other / unclassified | “L-lysine monohydrochloride is also an essential amino acid” NCT06580145 ↗ |
| Route | Oral | “Each test day will involve the ingestion of 70 capsules.” NCT01208324 ↗ |